A 5-year-old French Bulldog presents with a two-day history of squinting and epiphora. On slit-lamp exam, you estimate the ulcer at 50 to 60 percent stromal depth — deeper than you’d like, but not yet a descemetocele. There’s no obvious melting, no positive fluorescein pooling in a central dimple, no iris visible. The question in front of you: do you refer now, or do you have a management window?
This is the clinical gray zone that general practitioners navigate regularly. Deep stromal ulcers — those involving more than half the corneal thickness but with Descemet’s membrane still intact — sit at the pivot point between medical management and surgical intervention. Getting that decision right determines whether the eye is saved and whether the client stays with your practice.
Here’s the framework for making that call, what you can do medically while the clock is running, and where amniotic eye drops fit into the combination protocol.
Understanding Stromal Depth: Why the 50% Threshold Matters
Corneal ulcers are classified by depth. Superficial ulcers involve only the epithelium and heal with standard medical management in three to five days. Stromal ulcers have penetrated into the collagen stroma — and the deeper they go, the narrower the remaining tissue barrier between the external environment and the intraocular contents.
At 50% stromal depth, ophthalmologist assessment is the standard recommendation. At 60 to 70%, urgent surgical evaluation is indicated. At 100% — where only Descemet’s membrane remains, visible as a transparent, fluid-filled bleb — you have a descemetocele, and the difference between that and globe perforation may be hours.
The 50% threshold isn’t arbitrary. Corneal stroma doesn’t regenerate the way epithelium does. When stromal tissue is lost, it doesn’t regrow — it heals by fibrosis (scar) or is replaced by graft material. Below 50%, medical management has a reasonable chance of stabilizing the ulcer and allowing epithelial bridging over the defect. Above 50%, the structural integrity of the globe is progressively at risk and the biological environment often can’t support closure without surgical reinforcement.
The practical challenge: estimating depth accurately without specialized equipment. Slit-lamp biomicroscopy gives the best assessment. If you don’t have access, a progressive increase in ulcer size at serial exams, obvious thinning of the cornea at the ulcer margin, or a gelatinous appearance to the stroma all suggest significant depth and warrant referral without waiting.
Deep Stromal Ulcers vs. Melting Ulcers: A Critical Distinction
These two entities are related but clinically distinct, and conflating them leads to both over- and under-treatment.
A deep stromal ulcer is defined by structural loss — stroma has been consumed, typically through infection or trauma, but the remaining tissue is structurally stable. The ulcer is deep, but it isn’t actively dissolving.
A melting ulcer (keratomalacia) is defined by active enzymatic degradation — proteolytic enzymes released by bacteria, particularly Pseudomonas aeruginosa, and by host inflammatory cells are actively liquefying the stroma in real time. A melting ulcer can progress from 30% to perforation within 24 hours. A deep but non-melting stromal ulcer may be stable for days.
The key diagnostic signal: tissue consistency. Stable deep ulcers have firm, defined margins. Melting ulcers have soft, gelatinous, indistinct margins — the characteristic “liquefied” appearance. A corneal cytology or culture can confirm bacterial species when you suspect melting, but clinical appearance is often enough to distinguish the two in-exam.
This distinction matters because the treatment urgency and the window for medical management are fundamentally different. Non-melting deep ulcers give you a 24 to 48 hour window to begin aggressive medical management and arrange referral. Melting ulcers do not.
Medical Management: The 24-48 Hour Window
For a deep stromal ulcer without active melting, you have a short but meaningful window to begin combination medical management while arranging ophthalmology consultation. The goals: prevent infection-driven progression, suppress enzymatic activity, support the healing environment, and protect the eye during transport or a waiting period.
Topical antibiotics — broad-spectrum coverage immediately. Don’t wait for culture results to start treatment. Tobramycin or a fluoroquinolone (ciprofloxacin, ofloxacin) applied every two to four hours provides broad-spectrum coverage while pending diagnostics. If you suspect Pseudomonas, fortified tobramycin or a combination of ciprofloxacin and cefazolin is the standard of care.
Anticollagenase therapy — essential, not optional. Even in the absence of obvious melting, matrix metalloproteinases (MMPs) are active in any infected or inflamed cornea. These enzymes degrade collagen and can convert a stable deep ulcer into a melting one. Topical autologous or equine serum applied every two to four hours provides MMP inhibitors. Oral doxycycline at subantimicrobial doses adds systemic anticollagenase support. N-acetylcysteine is an alternative if serum isn’t available.
Amniotic eye drops — adjuvant for the healing environment. EyeQ amniotic eye drops contribute a different mechanism to the protocol: growth factor delivery and inflammatory modulation. Corneal epithelialization requires EGF (epidermal growth factor), HGF, and KGF — growth factors that are preserved in amniotic membrane extract and that support the migration of epithelial cells across the wound surface. Trusted by over 90% of veterinary ophthalmologists and used in over 100,000 eyes, EyeQ positions amniotic therapy alongside antibiotics and anticollagenases as a standard component of combination management — not a standalone treatment, but a meaningful addition that supports the biology the cornea needs to stabilize.
Pain management and globe protection. Atropine 1% for cycloplegia reduces ciliary spasm pain and prevents posterior synechia. An E-collar is non-negotiable. The greatest risk during the medical management window is the patient rubbing the eye and mechanically perforating the cornea before surgical repair can occur.
Set a clear reassessment timeline: recheck at 24 hours. If the ulcer is stable or improving, continue the protocol. If it has progressed — deeper, larger, softer margins, increased ocular pain — escalate to immediate referral.
When Surgery Is the Right Call
For ulcers above 60 to 70% stromal depth, the referral conversation shouldn’t wait for medical management to fail. It should happen at the first exam, while you begin the protocol above as a bridge.
Surgical options for deep stromal ulcers include:
- Conjunctival pedicle graft — the workhorse procedure. A flap of vascularized conjunctiva is rotated over the defect, providing structural support and a direct blood supply. Success rates of 85 to 90% in experienced hands. Graft is typically trimmed or left to pigment over time.
- Corneoscleral transposition — for central defects where a conjunctival graft would impair vision. More technically demanding.
- Amniotic membrane grafting — surgical-grade freeze-dried amniotic membrane as a structural overlay. A 2025 study in Veterinary Ophthalmology showed 100% healing in 20 eyes over a mean of 17 days with freeze-dried amniotic membrane grafts.
Prognosis framing for clients: conjunctival graft surgery is successful in 85 to 90% of cases. Cost ranges widely by region and facility but typically falls between $1,500 and $3,500 at specialty centers. The alternative — waiting while an ulcer progresses to perforation — carries a much higher risk of globe loss. Most clients, presented with those options clearly, make the decision the eye needs.
After Surgical Repair: The Continued Role of Amniotic Drops
Post-surgical corneal recovery benefits from the same growth factor support that aids medical management. After conjunctival graft or amniotic membrane grafting, the corneal epithelium still needs to bridge across the repaired surface. EyeQ supports that phase — the same mechanisms (EGF, HGF, inflammatory modulation) that aid pre-surgical stabilization continue to support post-operative epithelialization and reduce the risk of surgical site complications.
Clinical Bottom Line
Deep stromal corneal ulcers demand a structured response: accurate depth assessment, immediate antibiotic and anticollagenase coverage, a short medical management window, and a clear referral plan for cases above 60% depth or showing any progression. The 24 to 48 hour window is not an opportunity to wait and see — it’s an opportunity to stabilize while preparing for the next decision.
EyeQ fits into this protocol as an evidence-supported adjuvant: growth factor delivery and inflammatory modulation at the critical phase when the corneal biology is either stabilizing or deteriorating. Combined with anticollagenase therapy and appropriate antibiotic coverage, it completes the medical management protocol that trusted ophthalmologists reach for in difficult corneal cases.
Learn how EyeQ supports both medical management and post-surgical recovery at RethinkHealing.com.

Keratoconjunctivitis sicca (KCS), often referred to as dry eye, is inflammation of the cornea and surrounding tissues due to inadequate production of tears. Tears are necessary to lubricate the cornea and remove debris or any infectious agents that come in contact with the eye. The tear film is a mixture of mucus, fatty liquid, and water.
